CLCC awarded £1m NIHR funding to address threatened miscarriage

Pioneering technology to address threatened miscarriage secures £1 million funding and moves towards clinical trials

Scientists developing a pioneering device designed to address threatened miscarriage have secured £1 million in NIHR funding to begin clinical trials

Designed to deliver vital doses of progesterone, the Callavid® device stands to help over 150,000 women each year in the UK

If approved, it would become the world’s first drug-device combination product to treat threatened miscarriage

See full press release here.

我们使用cookie改善您的网站体验。我们使用必要的cookie以确保网站功能正常运行并维持安全。这些cookie始终需要打开。点击“接受cookie”,即表示您同意将cookie储存在您的设备上以增强网站导航,分析网站使用,并协助我们的营销工作。请查看我们的隐私政策,了解进一步详情。